1. Home
  2. WRAP vs ACOG Comparison

WRAP vs ACOG Comparison

Compare WRAP & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wrap Technologies Inc.

WRAP

Wrap Technologies Inc.

HOLD

Current Price

$2.53

Market Cap

111.3M

Sector

Industrials

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$6.55

Market Cap

115.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WRAP
ACOG
Founded
2016
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Ordnance And Accessories
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
111.3M
115.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WRAP
ACOG
Price
$2.53
$6.55
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
507.0K
106.2K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,133,000.00
$7,427,199.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$132.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.20
$3.75
52 Week High
$3.00
$11.54

Technical Indicators

Market Signals
Indicator
WRAP
ACOG
Relative Strength Index (RSI) 57.38 58.35
Support Level $2.09 $5.61
Resistance Level $2.62 $6.91
Average True Range (ATR) 0.20 0.54
MACD 0.01 0.13
Stochastic Oscillator 67.34 78.74

Price Performance

Historical Comparison
WRAP
ACOG

About WRAP Wrap Technologies Inc.

Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel worldwide. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: